LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Lilly’s emphasis on patient-reported outcomes (PROs) has differentiated Omvoh from its competitors, and the company will further its case at ECCO 2025 by unveiling results from the LUCENT-URGE ...